Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Baxter
Mallinckrodt
McKesson
Colorcon

Last Updated: January 19, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for AP1903


Email this page to a colleague

« Back to Dashboard

What is the drug development status for AP1903?

AP1903 is an investigational drug.

There have been 27 clinical trials for AP1903. The most recent clinical trial was a Phase 1 trial, which was initiated on December 27th 2018.

The most common disease conditions in clinical trials are Myelodysplastic Syndromes, Preleukemia, and Precursor Cell Lymphoblastic Leukemia-Lymphoma. The leading clinical trial sponsors are Bellicum Pharmaceuticals, Baylor College of Medicine, and Center for Cell and Gene Therapy, Baylor College of Medicine.

There are fourteen US patents protecting this investigational drug and two hundred and eight international patents.

Recent Clinical Trials for AP1903
TitleSponsorPhase
Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid TumorsCenter for Cell and Gene Therapy, Baylor College of MedicinePhase 1
Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid TumorsBaylor College of MedicinePhase 1
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Hepatocellular CarcinomaCenter for Cell and Gene Therapy, Baylor College of MedicinePhase 1

See all AP1903 clinical trials

Clinical Trial Summary for AP1903

Top disease conditions for AP1903
Top clinical trial sponsors for AP1903

See all AP1903 clinical trials

US Patents for AP1903

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AP1903 ⤷  Try it Free Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) ⤷  Try it Free
AP1903 ⤷  Try it Free CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) ⤷  Try it Free
AP1903 ⤷  Try it Free Treatment of cancer using a CLL-1 chimeric antigen receptor Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) ⤷  Try it Free
AP1903 ⤷  Try it Free Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) ⤷  Try it Free
AP1903 ⤷  Try it Free Compositions and methods for treatment of cancer Aleta Biotherapeutics Inc. (Natick, MA) ⤷  Try it Free
AP1903 ⤷  Try it Free Treatment of cancer using a CD123 chimeric antigen receptor The Trustees of the University of Pennsylvania (Philadelphia, PA) Novartis AG (Basel, CH) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AP1903

Drugname Country Document Number Estimated Expiration Related US Patent
AP1903 Argentina AR102035 2034-07-21 ⤷  Try it Free
AP1903 Australia AU2015292744 2034-07-21 ⤷  Try it Free
AP1903 Australia AU2020202726 2034-07-21 ⤷  Try it Free
AP1903 Brazil BR112017001183 2034-07-21 ⤷  Try it Free
AP1903 Canada CA2955386 2034-07-21 ⤷  Try it Free
AP1903 China CN106687483 2034-07-21 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Baxter
Mallinckrodt
McKesson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.